Regarding the Transfer of the Bioprocess Materials Business
JSR Corporation (Representative Director, CEO and President: Tetsuro Hori; hereinafter “JSR”) announces that it entered into an agreement to transfer its bioprocess materials business to Merck (Chair of the Executive Board and CEO: Belén Garijo; hereinafter “Merck”), subject to closing conditions. The proposed transaction is expected to close by the end of the second quarter of 2026.
Based in Belgium, the chromatography business delivers chromatography solutions to pharmaceutical and biotech manufacturers around the world. Renowned for its high-performance Amsphere™ A3 and Amsphere™ A+ Protein A resins, the business provides superior purification performance and process robustness across a broad spectrum of monoclonal antibodies. The Amsphere™ Protein A resins, developed through close collaboration among JSR group companies including JSR, KBI Biopharma, and JSR Life Sciences, have set new standards in purification efficiency.
Protein A chromatography is essential for the purification of monoclonal antibodies and therapeutic proteins, critical for treating cancers, autoimmune diseases, and infectious conditions. This process ensures high purity, improved drug safety, and enhanced manufacturing efficiency, ultimately accelerating patient access to innovative treatments.
The Life Science business of Merck* brings a robust portfolio of downstream solutions to the table, encompassing advanced filtration technologies, chromatography resins, buffers and chemicals, hardware and systems, integrated technologies, and validation services. These offerings empower customers to streamline drug development and manufacturing with enhanced speed, safety, and reliability.
This proposed strategic business transfer aligns with JSR’s vision to concentrate resources on high-impact areas where we can drive the most value for our partners and customers. We are excited to see JSR‘ｓinnovative technology continue to thrive under Merck's global platform, enabling faster and more reliable delivery of life-changing therapies.
William Blair & Company, LLC is serving as exclusive financial advisor to JSR Corporation.
*The Life Science business of Merck operates as MilliporeSigma in the United States and Canada.
Share with friends:
JSR Micro NV in the spotlights for Worldexpo Japan
Voka will be heading to the World Expo in Japan this May and is shining the spotlight on some of Belgium's top companies. JSR is among the chosen few! They recently interviewed several departments to showcase their story.
JSR Corporation is pleased to announce the release of the promotional film for the DAVOS 2025 campaign.
In order to strengthen our branding and expand recognition in the global market, we are collaborating with the DAVOS 2025 campaign and launching promotional activities in conjunction with the World Economic Forum (WEF). This film is now go-live on CBS News website. Please check the film via the link provided below.
17 September 2024
JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
JSR Life Sciences, a JSR Group company, today announced the launch of its next generation protein A chromatography resin, Amsphere™ A+.
30 November 2023
New Energy Collaborative Aims to Accelerate Creation of Low-Carbon Energy Access in Asia-Pacific for the Semiconductor Climate Consortium
2 November 2022
JSR Joins Semiconductor Climate Consortium as Founding Member
JSR Corporation today announced it has become a founding member of the new Semiconductor Climate Consortium (SCC), a group formed with other companies from across the semiconductor value chain and SEMI, the global industry association representing the electronics manufacturing and design supply chain.
13 October 2022
JSR Electronic Materials Korea to be a JSR Wholly Owned Subsidiary
SR Corporation (Representative Director, CEO: Eric Johnson, “JSR”) announced today that it has signed a Share Purchase Agreement to acquire the 60% of shares held by PERI Corporation (“PERI”) and make JSR Electronic Materials Korea Co., Ltd. ("JEMK") a wholly owned subsidiary of JSR. JEMK is a joint venture between PERI and JSR, which is the sales agent/distributor of its Electronic Materials business in Korea.
15 March 2022
JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
11 October 2021
JSR Micro NV is proud to break ground on construction of our new wastewater treatment plant!
22 September 2021
JSR to establish a new subsidiary for Semiconductor Material Business in Singapore
